Rhenman & Partners Asset Management’s Coherus Oncology CHRS Stock Holding History

Rhenman & Partners Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-290,000	Closed	-$5.88M	–	95
2019 Q3	$5.88M	Sell	290,000 -100,000	-26%	-$2M	0.74%	51
2019 Q2	$8.62M	Sell	390,000 -61,131	-14%	-$1.06M	0.95%	44
2019 Q1	$6.15M	Buy	451,131 +130,000	+40%	+$1.73M	0.72%	55
2018 Q4	$2.91M	Sell	321,131 -10,000	-3%	-$116K	0.33%	66
2018 Q3	$5.46M	Sell	331,131 -18,869	-5%	-$334K	0.55%	62
2018 Q2	$4.9M	Hold	350,000	–	–	0.5%	60
2018 Q1	$3.87M	Hold	350,000	–	–	0.48%	60
2017 Q4	$3.08M	Buy	350,000 +170,000	+94%	+$1.82M	0.42%	66
2017 Q3	$2.4M	Buy	180,000 +11,128	+7%	+$147K	0.31%	73
2017 Q2	$2.42M	Buy	168,872 +57,515	+52%	+$1.11M	0.35%	75
2017 Q1	$2.35M	Hold	111,357	–	–	0.37%	77
2016 Q4	$3.13M	Sell	111,357 -20,000	-15%	-$560K	0.6%	62
2016 Q3	$3.52M	Hold	131,357	–	–	0.56%	64
2016 Q2	$2.22M	Buy	+131,357	New	+$2.47M	0.39%	70

Other funds holding CHRS

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Rhenman & Partners Asset Management's CHRS Position: Q4 2019 in Review

Rhenman & Partners Asset Management sold out of Coherus Oncology (CHRS) in Q4 2019, closing a stake of 290,000 shares — an estimated $5.88M sold.

Rhenman & Partners Asset Management first reported a position in CHRS in Q2 2016 and held it in 14 quarters. The position peaked at $8.62M in Q2 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q4 2019.

Rhenman & Partners Asset Management reported no remaining Coherus Oncology position as of Q4 2019 after selling out during the quarter.
Rhenman & Partners Asset Management sold 290,000 Coherus Oncology shares in Q4 2019, an estimated $5.88M.
Rhenman & Partners Asset Management first reported a position in Coherus Oncology in Q2 2016 and held it in 14 quarters.
Rhenman & Partners Asset Management's Coherus Oncology position peaked at $8.62M in Q2 2019.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2019.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.